当前位置: 首页 > 期刊 > 《医学信息》 > 2018年第22期
编号:13339527
雷珠单抗治疗湿性年龄相关性黄斑变性的视力改善与黄斑形态学变化相关性分析(3)
http://www.100md.com 2018年6月4日 《医学信息》 2018年第22期
     [4]Pedrosa AC,Sousa T,Pinheiro-Costa J,et al.Treatment of neovascular age-related macular degeneration with anti-VEGF agents:predictive factors of long-term visual outcomes[J].J Ophthalmol,2017(6):1-10.

    [5]李铭,魏伟.湿性年龄相关性黄斑变性的治疗进展[J].国际眼科杂志,2015,15(2):251-254.

    [6]Schauwvlieghe AME,Dijkman G,Hooymans JM,et al.Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration:The BRAMD Study[J].PLos One,2016,11(5):e0153052-e0153068.

    [7]郑燕林,彭晓丽,陈廷,等.Lucentis治疗黄斑脉络膜新生血管1年的临床疗效观察[J].眼科新进展,2016,36(4):348-351.

    [8]赵度然,李志,李寿玲.Ranibizumab治疗渗出型老年黄斑变性的1年疗效观察及视力恢复的预测因素分析[J].临床眼科杂志,2017,25(3):223-227.

    [9]Vottonen Paakkonen A,Tarkka IM,et al.Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients[J].Acta Ophthalmol,2015,93(7):621-625.

    [10]Ou WC,Brown DM,Payne JF,et al.Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases[J].Am J Ophthalmol,2017,180(5):8-17.

    收稿日期:2018-9-15;修回日期:2018-9-25

    編辑/王海静, 百拇医药(王小堂 谢安明)
上一页1 2 3